SUTRO BIOPHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SUTRO BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $24.57M.
- SUTRO BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $91.41M.
- SUTRO BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2024 was $24.57M.
- SUTRO BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2020 was $227.25M.
- SUTRO BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2018 was $74.44M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $24.57M 10-K · filed 2026-03-23 | |
| 2024-06-30 | $24.57M 10-Q · filed 2025-11-06 | |
| 2020-12-31 | $227.25M 10-K · filed 2023-03-30 | |
| 2020-06-30 | $91.41M 10-Q · filed 2021-11-10 | |
| 2018-12-31 | $74.44M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |